Minimizing DILI risk in drug discovery - A screening tool for drug candidates.
about
Key Challenges and Opportunities Associated with the Use of In Vitro Models to Detect Human DILI: Integrated Risk Assessment and Mitigation PlansDrug-induced liver injury: recent advances in diagnosis and risk assessment.Revisiting the Metabolism and Bioactivation of Ketoconazole in Human and Mouse Using Liquid Chromatography-Mass Spectrometry-Based Metabolomics.Current limitations and future opportunities for prediction of DILI from in vitro.The Promise of New Technologies to Reduce, Refine, or Replace Animal Use while Reducing Risks of Drug Induced Liver Injury in Pharmaceutical Development.Drug rechallenge following drug-induced liver injury.Fasiglifam (TAK-875): Mechanistic Investigation and Retrospective Identification of Hazards for Drug Induced Liver Injury.Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury.Evaluation of DILI Predictive Hypotheses in Early Drug Development.Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective.Measures of BSEP Inhibition In Vitro Are Not Useful Predictors of DILI.A Model to predict severity of drug-induced liver injury in humans.Synergistic Cytotoxicity from Drugs and Cytokines In Vitro as an Approach to Classify Drugs According to Their Potential to Cause Idiosyncratic Hepatotoxicity: A Proof-of-Concept Study.Early Alterations of Bile Canaliculi Dynamics and the Rho Kinase/Myosin Light Chain Kinase Pathway Are Characteristics of Drug-Induced Intrahepatic Cholestasis.
P2860
Q28075991-0D44ECD3-DAD9-42F6-886E-148B872C3063Q30235089-BC2B5697-41A2-4724-91F2-DC75C5FB99C6Q37729280-3FC81D04-8FE2-4CB7-906B-C302595F0ACFQ38739197-739F2E73-CE70-4794-98C8-7EFD57DABFE4Q38774776-69BBB70E-01F4-4B83-8787-66926177D115Q38906878-77DF1A4D-D14A-4BD7-8E20-374481F13D37Q38958120-6CB6038D-A2F3-4759-8800-8AC75EDFC104Q41051252-FDF460D0-2DBE-4BCD-AA23-4AEEBE3DAA98Q46268821-A2BF7610-D35C-43CA-93BD-E025F2820F4BQ48011500-487458CB-E2F9-419E-ACD5-64D796BBD2CAQ49615812-5ED8B526-E804-4800-93C9-AD0D8B6308BCQ50627145-7A21A6F7-57DF-4227-A0A6-AC7519E3BBA8Q50902309-495B1B91-E2B4-45D1-9D2E-2F060355E1D6Q51563626-E7B0A313-CE63-4750-B1B3-2021A33610A4
P2860
Minimizing DILI risk in drug discovery - A screening tool for drug candidates.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Minimizing DILI risk in drug discovery - A screening tool for drug candidates.
@en
Minimizing DILI risk in drug discovery - A screening tool for drug candidates.
@nl
type
label
Minimizing DILI risk in drug discovery - A screening tool for drug candidates.
@en
Minimizing DILI risk in drug discovery - A screening tool for drug candidates.
@nl
prefLabel
Minimizing DILI risk in drug discovery - A screening tool for drug candidates.
@en
Minimizing DILI risk in drug discovery - A screening tool for drug candidates.
@nl
P2093
P1433
P1476
Minimizing DILI risk in drug discovery - A screening tool for drug candidates.
@en
P2093
A C Cascais
C McGinnis
C Zihlmann
E Di Lenarda
P304
P356
10.1016/J.TIV.2015.09.019
P433
P577
2015-09-22T00:00:00Z